- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00547183
Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection
October 18, 2007 updated by: Eli Lilly and Company
A Randomized, Double-Blind, Parallel-Design, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil (2.5 mg and 5 mg) Administered Once Daily to Men With Diabetes Mellitus and Erectile Dysfunction
Study to evaluate the safety and effectiveness of 2.5 mg and 5 mg tadalafil when taken by men with diabetes mellitus who have problems getting and maintaining an erection.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
298
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Genthin, Germany
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- History of erectile dysfunction for at least 3 months.
- Currently have diabetes mellitus of at least 3 months duration.
- Agree to not use any other ED treatment during the study.
- Anticipate the same female sexual partner for the study.
- Must be willing to make the required number of sexual attempts.
Exclusion Criteria:
- History of other primary sexual disorder
- Treatment with nitrates or potent CYP3A4 inhibitors
- Have a penile implant or clinically significant penile deformity
- History of certain heart problems
- Have kidney or liver problems
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 1
|
Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
|
Active Comparator: 2
2.5 mg tadalafil
|
2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
Other Names:
5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
Other Names:
|
Active Comparator: 3
5 mg tadalafil
|
2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
Other Names:
5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Effectiveness measured by IIEF score of questions 1-5 and 15 plus the percentages of positive responses to questions 2 and 3 in the SEP diary
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the GAQ, SEP, IIEF, SEAR, and RSE scores.
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Porst H, Gacci M, Buttner H, Henneges C, Boess F. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. Eur Urol. 2014 Feb;65(2):455-64. doi: 10.1016/j.eururo.2013.09.037. Epub 2013 Oct 2.
- Shabsigh R, Seftel AD, Kim ED, Ni X, Burns PR. Efficacy and safety of once-daily tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline. J Sex Med. 2013 Mar;10(3):844-56. doi: 10.1111/j.1743-6109.2012.02898.x. Epub 2012 Oct 4.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2004
Study Completion (Actual)
May 1, 2005
Study Registration Dates
First Submitted
October 18, 2007
First Submitted That Met QC Criteria
October 18, 2007
First Posted (Estimate)
October 22, 2007
Study Record Updates
Last Update Posted (Estimate)
October 22, 2007
Last Update Submitted That Met QC Criteria
October 18, 2007
Last Verified
October 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8702
- H6D-MC-LVFZ
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Impotence
-
National Taiwan University HospitalAbbottUnknown
-
University Hospital, MontpellierCompletedPainful Hip | Fonctional Impotence After Minor Trauma (Fall)France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedImpotenceGreece, Italy, Spain, Russian Federation, Canada, Israel, United Kingdom, France
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
Rambam Health Care CampusUnknown
-
Rio de Janeiro State UniversityCompletedErectile Dysfunction | Impotence
-
University Hospital, SaarlandNovartisWithdrawn
-
PfizerCompletedImpotenceNorway, United Kingdom
-
Eli Lilly and CompanyICOS CorporationCompletedImpotenceUnited States, Austria, France, Germany, Mexico
-
Boston Scientific CorporationCompletedErectile Dysfunction | ImpotenceUnited States, Canada
Clinical Trials on tadalafil
-
Institute for the Study of Urological Diseases,...RecruitingErectile DysfunctionGreece
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedBenign Prostatic HyperplasiaJapan
-
Centro Universitario de Ciencias de la Salud, MexicoUnknownObesity and Erectile DysfuntionMexico
-
Futura Medical Developments Ltd.CompletedErectile DysfunctionUnited States, Bulgaria, Georgia, Poland
-
Saint Petersburg State University, RussiaRecruitingErectile DysfunctionRussian Federation
-
University of PernambucoUnknown
-
Cairo UniversityUnknownErectile DysfunctionEgypt
-
Cedars-Sinai Medical CenterCompleted
-
Mark FeinglosEli Lilly and Company; Duke UniversityWithdrawnNausea | Vomiting | Gastroparesis | Diabetic GastroparesisUnited States